Sumitomo Mitsui Trust Group Inc. Has $82.05 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sumitomo Mitsui Trust Group Inc. raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 198,450 shares of the company's stock after purchasing an additional 916 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.24% of IDEXX Laboratories worth $82,047,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in IDXX. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in IDEXX Laboratories by 400.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 500 shares of the company's stock worth $253,000 after purchasing an additional 400 shares in the last quarter. Gateway Investment Advisers LLC boosted its stake in shares of IDEXX Laboratories by 1.2% during the 3rd quarter. Gateway Investment Advisers LLC now owns 11,075 shares of the company's stock worth $5,595,000 after acquiring an additional 134 shares in the last quarter. Carnegie Investment Counsel bought a new stake in IDEXX Laboratories during the third quarter worth approximately $205,000. CHICAGO TRUST Co NA boosted its position in IDEXX Laboratories by 29.3% during the third quarter. CHICAGO TRUST Co NA now owns 3,990 shares of the company's stock worth $2,016,000 after purchasing an additional 904 shares during the period. Finally, Crestmont Private Wealth LLC boosted its position in IDEXX Laboratories by 14.4% during the third quarter. Crestmont Private Wealth LLC now owns 525 shares of the company's stock worth $265,000 after purchasing an additional 66 shares during the period. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX stock traded up $2.41 during midday trading on Thursday, hitting $459.76. The stock had a trading volume of 601,058 shares, compared to its average volume of 718,152. The stock has a 50-day simple moving average of $430.12 and a 200 day simple moving average of $453.26. The firm has a market capitalization of $37.65 billion, a price-to-earnings ratio of 43.09, a P/E/G ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 13,330 shares of company stock valued at $6,161,276. Company insiders own 2.11% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Morgan Stanley decreased their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Wednesday, February 5th. Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday. Finally, Leerink Partners started coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price target for the company. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.